Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.

Paola Perini1, Massimiliano Calabrese, Michela Tiberio

  • 1Multiple Sclerosis Centre of Veneto Region First Neurology Clinic, University Hospital of Padova, Via Giustiniani 5, 35128 Padova, Italy.

Journal of Neurology
|April 13, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative MRI Uncovers Subtle Cortical Damage in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Annals of clinical and translational neurology·2026
Same author

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal of neurology·2026
Same author

Paramagnetic Rim Lesions and Choroid Plexus Volume at Diagnosis Are Associated With Cognitive Progression Independent of Relapse and MRI Activity in Early Relapsing-Remitting Multiple Sclerosis.

Annals of clinical and translational neurology·2026
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Rethinking prognosis in multiple sclerosis: a multiaxial perspective.

Nature reviews. Neurology·2026

Cyclophosphamide and mitoxantrone equally reduced relapse rates and disability progression in secondary progressive multiple sclerosis (SPMS) patients. Cyclophosphamide offers a less expensive therapeutic option for rapidly deteriorating SPMS.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Secondary progressive multiple sclerosis (SPMS) is characterized by continuous neurological deterioration.
  • Limited effective treatment options exist for managing SPMS progression.

Purpose of the Study:

  • To compare the efficacy and safety of cyclophosphamide (Cy) versus mitoxantrone (Mito) in SPMS patients.
  • To evaluate the cost-effectiveness of these two therapeutic protocols.

Main Methods:

  • A two-year randomized study involving 50 SPMS patients.
  • Clinical evaluations (relapse rate, disability progression) and magnetic resonance imaging (MRI) were performed.
  • Safety profiles and treatment costs were analyzed.

Main Results:

Related Experiment Videos

  • Both Cy and Mito significantly reduced relapse rates and disability progression.
  • Identified subgroups of responders in both treatment groups with significant EDSS score improvement.
  • Both drugs demonstrated acceptable safety profiles, with Cy being significantly less expensive.

Conclusions:

  • Cyclophosphamide and mitoxantrone show comparable efficacy in treating SPMS.
  • Cyclophosphamide presents a cost-effective therapeutic option for rapidly progressing SPMS.
  • Further consideration of cyclophosphamide is warranted for SPMS management.